Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons

Brain Research

Volumn 743, Issue 1-2, 1996, Pages 278-283

  Cheng, Neng Neng ^a   Maeda, Takehiko ^a   Kume, Toshiaki ^a   Kaneko, Satoshi ^a   Kochiyama, Hanae ^a   Akaike, Akinori ^a   Goshima, Yoshio ^b   Misu, Yoshimi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

ascorbic acid; autoxidation; dopamine; glutamate; L DOPA; neurotoxicity; striatum

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; ASCORBIC ACID; DIZOCILPINE; DOPAMINE; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ARTICLE; AUTOOXIDATION; CELL CULTURE; CONTROLLED STUDY; CORPUS STRIATUM; FETUS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; ASCORBIC ACID; CELL AGING; CELL DEATH; CELLS, CULTURED; CORPUS STRIATUM; DOPAMINE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; NEURONS; NEUROTOXINS; OXIDATION-REDUCTION; RATS; RATS, WISTAR;

EID: 0030462233     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)01056-6     Document Type: Article

References (30)

1. Abarca, J., Gysling, K., Roth, RH. and Bustos, G., Changes in extracellular levels of glutamate and aspartate in rat substantia nigra induced by dopamine receptor ligands: in vivo microdialysis studies, Neurochem. Res., 20 (1995) 159-169.
2. Akaike, A., Tamura, Y., Sato, Y., Ozaki, K., Matsuoka, R., Miura, S. and Yoshinaga, T., Cholecystokinin-induced protection of cultured cortical neurons against glutamate cytotoxicity, Brain Res., 557 (1992) 303-307.
3. Amano, T., Ujihara, H., Matsubayashi, H., Sasa, M., Yokota, T., Tamura, Y. and Akaike, A., Dopamine-induced protection of striatal neurons against kainate receptor-mediated cytotoxicity in vitro, Brain Res., 655 (1994) 61-69.
4. Basma, A.N., Morris, E.J., Nicklas, W.J. and Geller, H.M., DOPA cytotoxicity to PC12 cells in culture is via its autoxidation, J. Neurochem., 64 (1995) 825-832.
5. Ben-Shachar, D. Zuk, R. and Glinka, Y., Dopamine neurotoxicity: inhibition of mitochondrial respiration, J. Neurochem., 64 (1995) 718-723.
6. Blin, J., Bonnet, A.M. and Agid, Y., Does levodopa aggravate Parkinson's disease? Neurology, 38 (1988) 1410-1416.
7. Cohen, G. and Heikkila, R.E., The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents, J. Biol. Chem., 249 (1974) 2447-2452.
8. Crowder, J.M. and Bradford, H.F., Inhibitory effects of noradrena-line and dopamine on calcium influx and neurotransmitter glutamate release in mammalian brain slices, Eur. J. Pharmacol., 143 (1987) 343-352.
9. Dexter, D.T., Carter, C.J. and Wells, F.R., Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease, J. Neurochem., 52 (1989) 381-389.
10. Fahn, S. and Bressman, S.B., Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment, Can. J. Neurol. Sci., 11 (1984) 200-206.
11. Fornstedt, B., Role of catechol autoxidation in the degeneration of dopamine neurons, Acta Neurol. Scand. Suppl., 129 (1990) 12-14.
12. Globus, M.Y.T., Busto, R. and Dietrich, W.D., Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and γ-aminobutyric acid studied by intracerebral microdialysis, J. Neurochem., 51 (1988) 1455-1464.
13. 2+-dependent and tetrodotoxin-sensitive release of endogenous glutamate from rat striatal slices, Brain Res., 617 (1993) 167-170.
14. Graham, D.G., Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro, Mol. Pharmacol., 14 (1978) 633-643.
15. Guylaine, M.D. and Zukin, R.S., Developmental regulation of mRNAs encoding rat brain kainate/AMPA receptors: a northern analysis study, J. Neurochem., 61 (1993) 2239-2246.
16. Hisanaga, K., Sagar, M.S. and Sharp, F.R., Ascorbate neurotoxicity in cortical cell culture, Ann. Neurol., 31 (1992) 562-565.
17. Lloyd, K.G., Davidson, L. and Hornykiewicz, O., The neurochemistry of Parkinson's disease: effect of L-DOPA therapy, J. Pharmacol. Exp. Ther., 195 (1975) 453-464.
18. Mena, M.A., Pardo, B., Paino, C.L. and Yebenes, J.G., Levodopa toxicity in fetal rat midbrain neurons in culture: modulation by ascorbic acid, NeuroReport, 4 (1993) 438-440.
19. Moore, R.Y. and Bloom, F.E., Central catecholamine neuron system: anatomy and physiology of the dopamine systems, Annu. Rev. Neurosci., 1 (1978) 129-169.
20. Mytilineou, C., Han, S.K. and Cohen, G., Toxic and protective effects of L-DOPA on mesencephalic cell cultures, J. Neurochem., 61 (1993) 1470-1478.
21. Olney, J.W., Zorumski, C.F., Stuwart, G.R., Price, M.T., Wang, G.J. and Labruyere, J, Excitotoxicity of DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's diseases, Exp. Neurol, 108 (1990) 269-272.
22. Perry, T.L., Godin, D.V. and Hansen, S., Parkinson's disease: a disorder to nigral glutathione deficiency? Neurosci. Lett., 33 (1982) 305-310.
23. Porras, A. and Mora, F., Dopamine-glutamate-GABA interactions and aging: studies in the striatum of the conscious rat, Eur. J. Neurosci., 7 (1995) 2183-2188.
24. Richter, C., Gogvadze, V., Laffranchi, R., Schlapbach, R., Schweizer, M., Suter, M., Walter, P. and Yaffee, M., Oxidants in mitochondria: from physiology to diseases, Biochim. Biophys. Acta, 1271 (1995) 67-74.
25. Riederer, P., Sofic, E., Rausch, W.D., Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains, J. Neurochem., 52 (1989) 515-520.
26. 2 dopamine agonist synergism: separate sites of action? Trends Pharmacol. Sci., 8 (1987) 295-299.
27. Rossor, M.N., Watkins, J., Brown, M.J., Reid, J.L. and Dollery, C.T., Plasma levodopa, dopamine and therapeutic response following levodopa therapy of parkinsonian patients, Brain Res., 46 (1980) 385-392.
28. Smith, T.S., Parker, W.D. and Bennett, J.P., L-DOPA increases nigral production of hydroxyl radicals in vivo: potential L-DOPA toxicity? NeuroReport, 5 (1994) 1009-1011.
29. Sonsalla, P.K., Nicklas, W.J. and Heikkila, R.E., Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity, Science, 243 (1989) 398-400.
30. + neurotoxicity by N-methyl-D-aspartate antagonists, Nature, 349 (1991) 414-418.